Chitin Analog AVR-25 Prevents Experimental Bronchopulmonary Dysplasia.
Publication/Presentation Date
9-1-2020
Abstract
Infants born extremely preterm are at a high risk of developing bronchopulmonary dysplasia (BPD) which is characterized by large, simplified alveoli, increased inflammation, disrupted and dysregulated vasculogenesis, decreased cell proliferation, and increased cell death in the lungs. Due to lack of specific drug treatments to combat this condition, BPD and its long-term complications have taken a significant toll of healthcare resources. AVR-25, a novel immune modulator experimental compound, was able to partially recover the pulmonary phenotype in the hyperoxia-induced experimental mouse model of BPD. We anticipate that AVR-25 will have therapeutic potential for managing human BPD.
Volume
9
Issue
3
First Page
225
Last Page
232
ISSN
2146-4618
Published In/Presented At
Das, P., Acharya, S., Shah, D., Agarwal, B., Prahaladan, V., & Bhandari, V. (2020). Chitin Analog AVR-25 Prevents Experimental Bronchopulmonary Dysplasia. Journal of pediatric intensive care, 9(3), 225–232. https://doi.org/10.1055/s-0040-1709994
Disciplines
Medicine and Health Sciences
PubMedID
32685255
Department(s)
Department of Pathology and Laboratory Medicine
Document Type
Article